Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Metabolic bone diseases

Building bone is best in glucocorticoid-induced osteoporosis

Nature Reviews Rheumatology volume 9, page 135 (2013)Cite this article

Subjects

In a randomized, comparator-controlled, phase III trial in men with glucocorticoid-induced osteoporosis (GIO), Glüer et al. found the bone-forming agent teriparatide to be more efficacious than the antiresorptive agent risedronate.

...teriparatide had increased efficacy over risedronate...

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Glüer, C. C. et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J. Bone Miner. Res. doi:10.1002/jbmr.1870

Download references

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Killock, D. Building bone is best in glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 9, 135 (2013). https://doi.org/10.1038/nrrheum.2013.16

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.16

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing